2021-11-09 20:18
publication
2021-11-09 20:18
–
–
Biomed Lublin’s net loss in the third quarter of 2021 amounted to PLN 577 thousand. PLN against 94 thousand. PLN profit a year ago – the company announced. In the fourth quarter, Biomed Lublin expects to improve its results year on year.
As stated in the quarterly report, the revenues of Biomed Lublin decreased in the third quarter to PLN 6.5 million from PLN 8.3 million, and EBITDA amounted to PLN 1.2 million compared to PLN 2.1 million a year ago.
After three quarters, the company’s revenues amounted to PLN 26.6 million, EBITDA was PLN 7.6 million, and the net profit was PLN 1.2 million. In the same period of 2020, sales amounted to PLN 28 million, EBITDA was almost PLN 7.3 million, and net profit was PLN 0.8 million.
“The leverage of our results is the sale of high-margin products – Onko BCG and Distreptazy. The great interest in our products means that we can enter new export markets, mainly European. The fourth quarter of this year looks promising. We expect better results in this period. sales, I am also confident about the results of the entire 2021. I expect that EBITDA will be higher than in 2020 “- said Maksymilian Świniarski, president of Biomed Lublin, quoted in the press release.
“We are also optimistic about the next year. We count on an increase in revenues thanks to the acquisition of new export contracts for the sale of Onko BCG, Distreptaza and other biotechnological products” – added the president.
The company’s short-term liabilities at the end of September this year amounted to PLN 17.9 million, i.e. PLN 6.7 million less than at the end of 2020. The net cash flow increased from approx. PLN 0.4 million to PLN 5.7 million.
“We are currently implementing our strategic investments as planned. We are negotiating a final agreement on financing the investment related to the construction of the Onko BCG plant and we should finalize the details soon. We have secured the financing of the Research and Development Center. The construction works are carried out as planned,” said Świniarski.
The company announced that the investments in CBR and the new Onko BCG plant are to cost about PLN 125 million, and their goal is to multiply production capacity and strengthen the company’s position on the global market of BCG product manufacturers. (PAP Biznes)
pel / ana /
–
